Cargando…

Use of Biologic Agents in Ocular Manifestations of Rheumatic Disease

Biologic agents have dramatically shifted the treatment paradigm for rheumatic disease. Use of these agents can decrease disease burden, allow the patient to be weaned from corticosteroids, and reduce the likelihood of relapse. Eye disease associated with rheumatic conditions may present with a wide...

Descripción completa

Detalles Bibliográficos
Autores principales: Kraus, Courtney L., Culican, Susan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3246731/
https://www.ncbi.nlm.nih.gov/pubmed/22229035
http://dx.doi.org/10.1155/2012/203819
_version_ 1782219980804194304
author Kraus, Courtney L.
Culican, Susan M.
author_facet Kraus, Courtney L.
Culican, Susan M.
author_sort Kraus, Courtney L.
collection PubMed
description Biologic agents have dramatically shifted the treatment paradigm for rheumatic disease. Use of these agents can decrease disease burden, allow the patient to be weaned from corticosteroids, and reduce the likelihood of relapse. Eye disease associated with rheumatic conditions may present with a wide range of signs and symptoms. This coexisting pathology should not be overlooked and should be considered a reason for initiation or continuation of biologic therapy. Additionally, many of the ocular manifestations of rheumatic disease respond preferentially to specific targeting molecules. This paper summarizes the available studies on the use, efficacy, and safety of biologic agents in the treatment of ocular manifestations of rheumatic disease.
format Online
Article
Text
id pubmed-3246731
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-32467312012-01-06 Use of Biologic Agents in Ocular Manifestations of Rheumatic Disease Kraus, Courtney L. Culican, Susan M. Int J Rheumatol Review Article Biologic agents have dramatically shifted the treatment paradigm for rheumatic disease. Use of these agents can decrease disease burden, allow the patient to be weaned from corticosteroids, and reduce the likelihood of relapse. Eye disease associated with rheumatic conditions may present with a wide range of signs and symptoms. This coexisting pathology should not be overlooked and should be considered a reason for initiation or continuation of biologic therapy. Additionally, many of the ocular manifestations of rheumatic disease respond preferentially to specific targeting molecules. This paper summarizes the available studies on the use, efficacy, and safety of biologic agents in the treatment of ocular manifestations of rheumatic disease. Hindawi Publishing Corporation 2012 2011-12-15 /pmc/articles/PMC3246731/ /pubmed/22229035 http://dx.doi.org/10.1155/2012/203819 Text en Copyright © 2012 C. L. Kraus and S. M. Culican. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Kraus, Courtney L.
Culican, Susan M.
Use of Biologic Agents in Ocular Manifestations of Rheumatic Disease
title Use of Biologic Agents in Ocular Manifestations of Rheumatic Disease
title_full Use of Biologic Agents in Ocular Manifestations of Rheumatic Disease
title_fullStr Use of Biologic Agents in Ocular Manifestations of Rheumatic Disease
title_full_unstemmed Use of Biologic Agents in Ocular Manifestations of Rheumatic Disease
title_short Use of Biologic Agents in Ocular Manifestations of Rheumatic Disease
title_sort use of biologic agents in ocular manifestations of rheumatic disease
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3246731/
https://www.ncbi.nlm.nih.gov/pubmed/22229035
http://dx.doi.org/10.1155/2012/203819
work_keys_str_mv AT krauscourtneyl useofbiologicagentsinocularmanifestationsofrheumaticdisease
AT culicansusanm useofbiologicagentsinocularmanifestationsofrheumaticdisease